INTRODUCTION
The dynamic interface between circulating blood elements and the vascular wall plays a key part in disease progression, particularly in patients with chronically diseased vessels or acute vascular injury. Endothelial dysfunction is an early manifestation of vascular disease and is a marker of atherosclerotic risk burden. 1 Moreover, coronary endothelial dysfunction (CED) in the absence of obstructive coronary disease has been shown to be associated with increased cardiac events [2] [3] [4] and might be a manifestation of systemic vascular injury or impaired vascular repair.
The presence of circulating endothelial cells 5 and of cells capable of assuming an endothelial phenotype-termed endothelial progenitor cells (EPCs)-has been demonstrated by studies of human and animal chimeras. 6, 7 These cells and hematopoietic progenitor cells (HPCs) are hypothesized to have a common precursor, the hemangioblast, [8] [9] [10] making both cell types possible subsets of bone-marrow-derived progenitor cells expressing CD34.
Several studies have reported decreased numbers of EPCs in established coronary disease 11 and in patients at raised risk of cardiovascular disease. [12] [13] [14] Decreased levels of EPCs have also been observed in patients with peripheral endothelial dysfunction and CED in the setting of established coronary artery disease. 15, 16 Therefore, EPCs have been suggested as potential therapeutic and diagnostic targets.
The concept of reduced circulating EPC concentrations in both early and overt vascular disease has, however, been challenged by controversy regarding the definition of and thus the enumeration of EPCs 17, 18 and by a study that has demonstrated increased EPC numbers in advanced coronary disease. 19 Furthermore, circulating EPC numbers, measured by flow cytometry, were increased in cardiac syndrome X, although numbers of colony-forming units (CFUs) were reduced. 20, 21 Unfortunately, no internationally standardized set of criteria for the definition of EPCs has yet been accepted.
S u M M a rY
Background Endothelial dysfunction is an early manifestation of atherosclerotic disease. Circulating cells that express CD34, including endothelial and hematopoietic progenitor cells, might play a part in the development and progression of atherosclerosis. The aim of this study was to evaluate the association between coronary endothelial dysfunction and concentrations of circulating CD34 + cell subsets.
Methods Intracoronary acetylcholine challenge was used to test for coronary endothelial dysfunction in 57 consecutive patients scheduled to undergo diagnostic coronary angiography and with no signs of substantial obstructive lesions. Mononuclear cells were extracted from whole blood samples taken from all patients, analyzed by flow cytometry for CD14, CD34, CD133, CD45, and vascular endothelial growth factor receptor 2 (VEGFR2), and cultured for functional analysis. By contrast, circulating HPCs have been rigorously defined based on their expression of CD34. The International Society of Hematotherapy and Graft Engineering (ISHAGE) criteria define circulating HPCs as CD34 + cells that express the common leukocyte antigen CD45 at a lower intensity than mature leukocytes and for which backscatter to the lymphocyte region can be measured by flow cytometry. 22 A subset of HPCs can also be identified by expression of CD133. There is evidence suggesting that circulating EPCs do not express CD45, 23 and they they differ from HPCs by expressing vascular endothelial growth factor receptor 2 (VEGFR2). 23, 24 Given the possible common precursor, however, it is likely that circulating cells that express CD34 include EPCs and HPCs.
This study was designed to test the hypothesis that CED without substantial coronary obstruction in humans is associated with an alteration in concentrations of circulating CD34 + cell subsets. These cell types might include those involved directly or indirectly in vascular repair.
METHODS Patients
This study was approved by the Mayo Clinic Institutional Review Board, and informed, written consent was obtained from all patients in advance of cardiac catheterization. Consecutive patients undergoing diagnostic coronary angiography for evaluation of coronary artery disease were eligible for inclusion in the study if they had no significant epicardial coronary artery stenoses (<30%). Patients with hematological malignancy, left ventricular ejection fraction less than 50%, severe renal, hepatic, or endocrine disease, or ongoing infection were excluded. Nitrates and calciumchannel blockers were withheld for 48 h before the start of the study.
Coronary endothelial function testing
Intracoronary acetylcholine challenge testing was performed as described previously. 2, 3 Briefly, an investigator unaware of the cell analysis results used a quantitative coronary angiography program (Medis Imaging Systems, Leiden, the Netherlands) ncpcardio_2007_350f1.eps to measure coronary artery diameter off-line at proximal, mid and distal segments. 25 Coronary blood flow (CBF) was calculated from the Doppler-derived time-velocity integral and vessel diameter as π × (coronary artery diameter/2) 2 × (average peak velocity/2). 2 We defined CED as a decrease in diameter to below 20% in epicardial vessels and/or an increase of less than 50% in microvascular CBF in response to the maximum dose of acetylcholine (10 −4 mol/l), compared with flow at baseline. 2, 3, 26 Flow cytometry
Samples of whole blood (5 ml) were obtained from the first 38 patients at the time of cardiac catheterization and were analyzed by flow cytometry for expression of CD14, CD34, CD133, CD45, and VEGFR2. We based the flow cytometry settings on those in the ISHAGE criteria. Aliquots of 100 μl whole blood were incubated with the following fluorochrome conjugated antibodies: To increase the sensitivity and specificity of the flow cytometric analysis and to provide cells for in vitro CFU analysis, 50 ml blood samples were taken to obtain buffy coat from another group of 19 patients at the time of cardiac catheterization. Briefly, 25 ml of whole blood was decanted over an equal volume of Ficoll-Paque® (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) and centrifuged for 25 min at 1600 RPM without brake as previously described. 27 The buffy coat was extracted and washed twice. Cells were counted and resuspended in seven 100 μl aliquots, each containing approximately 10 6 cells, of phosphatebuffered saline for fluorescence-activated cell sorter analysis. After an Fc-receptor-blocking antibody (Miltenyi Biotec, Bergisch Gladbach, Germany) was added to each tube, cells were incubated with fluorochrome-conjugated antibodies to CD34-FITC, CD45-APC, and CD133-PE (Miltenyi Biotec) and a biotinylated goat antibody to human VEGFR2 (R&D Systems), which was subsequently labeled with Streptavidin-PerCP (BD Biosciences). Murine IgG1 (R&D Systems) conjugated to Alexa 488-PE (Molecular Probes) and rat anti-mouse PerCP and IgG1-APC (BD Biosciences) were used as isotype controls.
CD34 + cells were analyzed using sequential gating strategies that conformed to ISHAGE criteria to enumerate CD45 + cells in a dim fluorescence range indicative of HPCs (CD45 dim ; Figure 1 ) 22 and CD45 -cell subsets ( Figure 2) ; 60,000 events per tube were analyzed. The equipment used was a BD FACS Canto benchtop analyzer (BD, Franklin Lakes, NJ), and then the files were analyzed using WinMDI version 2.8 software. 28 Cells extracted from the buffy coat were counted and plated on to six fibronectin-coated wells in a 12-well plate at a density of 2-3 × 10 6 cells per well and incubated at 37°C in EGM-2 growth medium (Cambrex, Walkersville, MD). After 48 h, unattached cells were replated onto six new fibronectin-coated wells. 13 changed every 2 days, and colonies were counted at day 7.
Statistical analyses
All data were analyzed using JMP version 6.0. 29 Demographic data were compared between groups using the Student t-test for continuous variables and the Fisher's exact test for categorical variables. Cell counts were not normally distributed (skewed to the left); therefore, they were compared between groups using the Wilcoxon test. Data are expressed as median (25%, 75%) for continuous variables. Bonferroni correction was used for multiple comparisons. Differences in cell counts were considered significant at P <0.01; significance was set at P <0.05 for all other analyses. Standardized cell counts are presented as a percentage of the total number of CD45 + cells (CD45 dim and CD45 bright )
RESULTS
The demographic data and the baseline laboratory values of the study population are outlined in Tables 1 and 2 . Differential leukocyte counts were similar in patients with and without CED. No significant differences were observed between groups in terms of age, medications, or cardiovascular risk factors, with the exception of gender and serum C-reactive protein level (both P = 0.02), although neither correlated with CD34 + /CD45 -or CD34 + /CD45 dim counts. Thirty-seven patients of the total population of 57 were found to have CED as assessed by intracoronary acetylcholine administration. The 57 patients were studied in two cohorts. In the initial cohort of 38 patients, a significant decrease in the CD34+CD45 dim counts standardized by the percentage of leukocytes in whole blood was noted among patients with abnormal response to acetylcholine (CED) (median 0.05% [25% percentile 0.03%, 75% percentile 0.07%] versus 0.02% [0.01%, 0.03%], respectively, in whole blood; P = 0.003; Figure 3 ). However, standardized CD34 + CD45 − cell counts did not differ between the groups (0.009% [0.005%, 0.02%] versus 0.003% [0.002%, 0.02%] in whole A decrease was observed in the total number of CFUs in patients with CED compared with those with normal coronary endothelial function (4 [2, 6] versus 11 [5, 23] CFUs per well, P = 0.02; Figure 5 ).
DISCUSSION
Concentrations of specific subsets of circulating CD34 + cells are decreased in patients with CED and early coronary atherosclerosis. The data support an association between CD34 + /CD45 dim / VEGFR2 -cells and CED in a population without significant obstructive disease. Furthermore, a decrease in CFUs (derived from HPCs) was also observed. However, no relationship with CED was observed with CD34 + /CD45 -/VEGFR2 + cells. Taken together, these data support the concept that, even in the early stages of atherosclerosis, there are decreases in specific circulating subsets of CD34 + cells. Despite the current findings, difficulties remain in defining and enumerating EPCs. Two distinct methods have been used for EPC characterizationflow cytometry and cell culture-but the validity of both definitions has been questioned. The flow cytometric definition has centered on the expression of CD34 on circulating cells since Asahara et al. 30 characterized blood-derived cells that form endothelial cells in culture as being the progeny of cells expressing this antigen. Most flow cytometry studies have quantified cells that express CD34 and VEGFR2, and a minority have also included expression of CD133. 9, [11] [12] [13] [14] [15] 20 The cell culture definition of EPCs centers on colonies of spindle-shaped cells, which appear when blood-derived mononuclear cells are cultured for 7 days. 12, 13, 19 Evidence has accumulated, however, that these spindle-shaped cells are of hematopoietic lineage and do not represent true EPCs. 27, 31, 32 Most studies that have used flow cytometry to characterize and enumerate circulating CD34 + progenitor cells do not describe expression of CD45. This information is thought to be critical to define two distinct circulating subpopulations-CD34 + cells of hematopoietic lineage and differentiation potential and cells whose differentiation potential is endothelial. 23, 33 CD34 + cells from bone marrow, umbilical cord blood, and mobilized peripheral blood have different differentiation potentials dependent on the presence or absence of CD45 expression. CD34 + cells that express CD45 do not form true endothelial cells in culture. On the other hand, CD34 + cells that do not express CD45 may give rise to sheets of cells of cobblestone morphology, which are distinctly endothelial. Therefore, CD34 + cells that do not express CD45 on flow cytometry might include cells capable of developing bona fide endothelial cells.
We analyzed CD34 + cell subsets in peripheral blood based on their CD45 expression. Most cells were CD34 + /CD45 dim and thus meet standard criteria for circulating HPCs. 22 A minority of circulating CD34 + cells did not express CD45 but did express VEGFR2, but only CD34 + cells that coexpressed CD45 were found to be reduced in number in patients with CED. Similarly, the numbers of CFUs were reduced in patients with CED. This finding probably reflects a hematopoietic origin of these cells.
The findings of this study support the hypothesis that CED and reduced numbers of circulating CD34 + cell subsets are integrally related ncpcardio_2007_350f3.eps in the early stages of coronary artery disease. This finding is distinct from that of Werner et al., 16 which indicated an association between CED and CD34 + /VEGFR2 + cell numbers being reduced in patients with later stages of coronary artery disease. The reduced numbers of circulating cells in CED might reflect homing and seeding of these cells in sites of vascular disease and repair. The presence of increased progenitor cells in atherosclerotic plaques has been demonstrated in human vascular tissue obtained at the time of CABG surgery. 34 The role of bone marrow-derived cells in sites of endothelial disease has yet to be elucidated, but there is growing evidence that it includes paracrine effects. [35] [36] [37] In addition, vascular progenitors might reside within the vessel wall itself 38 and remain quiescent until triggered by a cytokine or growth factor signal, perhaps from a circulating cell of bone marrow origin. Alternatively, the reduced number of cells found in this study may reflect impaired production from bone marrow as a systemic manifestation of endothelial dysfunction. Additional studies will be required to determine the basis for this reduction. Any study of rare peripheral blood cells risks nonspecificity and the inability to discriminate between signal and noise. Quantification of rare CD34 + /CD45 -cells represents such a challenge due to nonspecific binding of antibodies and background autofluorescence. Alternative methods to detect such rare cells will be required to overcome these inherent potential limits of flow cytometry. Additionally, the size of the population studied prevents further detailed analysis of covariates that might generate hypotheses concerning the mechanism of this associated decrease in CD34 + subsets.
Demonstration of differential regulation of CD34 + cells in CED required the use of rigorous international standards of analysis. Our results support the hypothesis that decreases in concentrations of specific circulating CD34 + cell subsets are an early manifestation of atherosclerosis and are associated with coronary endothelial dysfunction. Additionally, this study highlights the need for rigid definitions of circulating subsets if the use of cellular biomarkers is to be advanced in cardiovascular disease. 
